Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
osimertinib (491) 491
science & technology (356) 356
life sciences & biomedicine (353) 353
oncology (263) 263
mutation (202) 202
lung cancer (197) 197
humans (153) 153
epidermal growth factor (141) 141
non-small cell lung cancer (124) 124
lung neoplasms - drug therapy (114) 114
respiratory system (108) 108
carcinoma, non-small-cell lung - drug therapy (105) 105
lung cancer, non-small cell (101) 101
tyrosine (101) 101
erbb receptors - genetics (100) 100
egfr (99) 99
lung neoplasms - genetics (91) 91
patients (90) 90
respiratory tract diseases (90) 90
carcinoma, non-small-cell lung - genetics (83) 83
nsclc (81) 81
t790m (81) 81
epidermal growth factor receptors (80) 80
protein kinase inhibitors - therapeutic use (79) 79
female (78) 78
non-small cell lung carcinoma (78) 78
chemotherapy (73) 73
kinases (69) 69
male (68) 68
epidermal growth factor receptor (67) 67
aged (63) 63
middle aged (62) 62
case report (61) 61
cancer therapies (59) 59
lung neoplasms - pathology (59) 59
metastasis (56) 56
protein-tyrosine kinase (56) 56
antineoplastic agents - therapeutic use (55) 55
cancer (54) 54
neoplasms. tumors. oncology. including cancer and carcinogens (53) 53
carcinoma, non-small-cell lung - pathology (51) 51
genetic aspects (51) 51
afatinib (49) 49
piperazines - therapeutic use (47) 47
adult (45) 45
development and progression (45) 45
care and treatment (44) 44
pharmacology & pharmacy (44) 44
analysis (43) 43
gefitinib (43) 43
tumors (42) 42
egfr mutation (40) 40
protein kinase inhibitors - pharmacology (39) 39
small cell lung carcinoma (39) 39
biopsy (38) 38
erbb receptors - antagonists & inhibitors (38) 38
tyrosine kinase inhibitor (37) 37
acquired resistance (36) 36
acrylamides - therapeutic use (36) 36
aged, 80 and over (36) 36
erlotinib (35) 35
lung cancer, small cell (35) 35
resistance (35) 35
treatment outcome (35) 35
aniline compounds - therapeutic use (34) 34
drug resistance, neoplasm - genetics (34) 34
adenocarcinoma (32) 32
antineoplastic agents - pharmacology (32) 32
non-small-cell lung cancer (32) 32
original (32) 32
growth factors (31) 31
clinical trials (26) 26
drug resistance (26) 26
animals (25) 25
health aspects (25) 25
piperazines - pharmacology (25) 25
research (25) 25
liquid biopsy (24) 24
medical research (24) 24
protein kinase inhibitors - adverse effects (24) 24
apoptosis (23) 23
general & internal medicine (23) 23
medicine, general & internal (23) 23
metastases (23) 23
protein kinase inhibitors - administration & dosage (23) 23
tyrosine kinase inhibitors (23) 23
drug therapy (21) 21
gene mutations (21) 21
mutation - genetics (21) 21
deoxyribonucleic acid--dna (20) 20
drug resistance, neoplasm - drug effects (20) 20
medicine, experimental (20) 20
t790m mutation (20) 20
disease progression (19) 19
egfr-tki (19) 19
lung neoplasms - mortality (19) 19
medical prognosis (19) 19
plasma (19) 19
retrospective studies (19) 19
acrylamides - pharmacology (18) 18
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (502) 502
Russian (6) 6
Korean (4) 4
Chinese (3) 3
Czech (1) 1
French (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Targeted Therapies for Resectable Lung Adenocarcinoma: A - DAURA Opens for Thoracic Oncologic Surgeons
by Jones, David R and Wu, Yi-Long and Tsuboi, Masahiro and Herbst, Roy S
The Journal of thoracic and cardiovascular surgery, ISSN 0022-5223, 02/2021
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
by Schoenfeld, Adam J and Chan, Joseph M and Kubota, Daisuke and Sato, Hiroki and Rizvi, Hira and Daneshbod, Yahya and Chang, Jason C and Paik, Paul K and Offin, Michael and Arcila, Maria E and Davare, Monika A and Shinde, Ujwal and Pe'er, Dana and Rekhtman, Natasha and Kris, Mark G and Somwar, Romel and Riely, Gregory J and Ladanyi, Marc and Yu, Helena A
Clinical cancer research, ISSN 1078-0432, 06/2020, Volume 26, Issue 11, pp. 2654 - 2663
Index Medicus | TKI | EGFR | acquired resistance | osimertinib
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
by Schoenfeld, A J and Arbour, K C and Rizvi, H and Iqbal, A N and Gadgeel, S M and Girshman, J and Kris, M G and Riely, G J and Yu, H A and Hellmann, M D
Annals of oncology, ISSN 0923-7534, 05/2019, Volume 30, Issue 5, pp. 839 - 844
TKI | irAE | PD-1 | EGFR | osimertinib | Life Sciences & Biomedicine | Oncology | Science & Technology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Emergence of NOTCH2-NTRK1 after osimertinib in a patient with lung adenocarcinoma with neuroendocrine differentiation
by Lin, Gengpeng and Liu, Yangli and Li, Hui and Chen, Shuyin and Guo, Yubiao
Clinical lung cancer, ISSN 1525-7304, 02/2021
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer
by Ohara, Shuta and Suda, Kenichi and Fujino, Toshio and Hamada, Akira and Koga, Takamasa and Nishino, Masaya and Chiba, Masato and Shimoji, Masaki and Takemoto, Toshiki and Soh, Junichi and Mitsudomi, Tetsuya
Lung cancer (Amsterdam, Netherlands), ISSN 0169-5002, 04/2021, Volume 154, pp. 84 - 91
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma-Letter
by Di Federico, Alessandro and Filippini, Daria M and Dall'Olio, Filippo G and Conci, Nicole and Minari, Roberta and Tiseo, Marcello and Ardizzoni, Andrea
Clinical cancer research, ISSN 1078-0432, 01/2020, Volume 26, Issue 2, pp. 518 - 519
Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Overcoming acquired resistance of EGFR-mutant NSCLC cells to osimertinib by combining osimertinib with the HDAC inhibitor, panobinostat (LBH589)
by Zang, Hongjing and Qian, Guoqing and Zong, Dan and Fan, Songqing and Owonikoko, Taofeek K and Ramalingam, Suresh S and Sun, Shi-Yong
Cancer, ISSN 0008-543X, 1/2020, Volume 126, Issue 9, pp. 2024 - 2033
lung cancer | LBH589 | osimertinib | apoptosis | acquired resistance | EGFR | HDAC
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment
by Beagan, Jamie J and Bach, Sander and van Boerdonk, Robert A and van Dijk, Erik and Thunnissen, Erik and van den Broek, Daan and Weiss, Janneke and Kazemier, Geert and Pegtel, D. Michiel and Bahce, Iis and Ylstra, Bauke and Heideman, Danielle A. M
Lung cancer (Amsterdam, Netherlands), ISSN 0169-5002, 07/2020, Volume 145, pp. 173 - 180
NSCLC | Osimertinib | EGFR-TKI | Circulating tumor DNA | EGFR | Monitoring
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
by Remon, J and Steuer, C E and Ramalingam, S S and Felip, E
Annals of oncology, ISSN 0923-7534, 01/2018, Volume 29, Issue suppl_1, pp. i20 - i27
Osimertinib | EGFR TKI | Acquired resistance | NSCLC | Life Sciences & Biomedicine | Oncology | Science & Technology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Osimertinib - a new treatment option for patients with EGFR mutation T790M
by Svatoň, Martin and Hrdá, Kristýna and Pešek, Miloš
Onkologie (Olomouc), ISSN 1802-4475, 2017, Volume 11, Issue 2, pp. 72 - 77
Osimertinib | T790M | AURA3 | EGFR
Journal Article
Details down arrow
11. Full Text Efficacy of osimertinib against EGFRvIII+ glioblastoma
by Chagoya, Gustavo and Kwatra, Shawn G and Nanni, Cory W and Roberts, Callie M and Phillips, Samantha M and Nullmeyergh, Sarah and Gilmore, Samuel P and Spasojevic, Ivan and Corcoran, David L and Young, Christopher C and Ballman, Karla V and Ramakrishna, Rohan and Cross, Darren A and Markert, James M and Lim, Michael and Gilbert, Mark R and Lesser, Glenn J and Kwatra, Madan M
Oncotarget, ISSN 1949-2553, 06/2020, Volume 11, Issue 22, pp. 2074 - 2082
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Biomimetic codelivery overcomes osimertinib-resistant NSCLC and brain metastasis via macrophage-mediated innate immunity
by Zhao, Pengfei and Zhang, Jiaxin and Wu, Aihua and Zhang, Meng and Zhao, Yuge and Tang, Yisi and Wang, Bing and Chen, Tianxiang and Li, Feng and Zhao, Qiang and Huang, Yongzhuo
Journal of controlled release, ISSN 0168-3659, 01/2021, Volume 329, pp. 1249 - 1261
Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors
by Ferrara, Miriam Grazia and Martini, Maurizio and D'Argento, Ettore and Forcella, Chiara and Vita, Emanuele and Di Noia, Vincenzo and Sperduti, Isabella and Bilotta, Mirna and Ribelli, Marta and Damiano, Paola and Cannella, Antonella and Stefani, Alessio and Pilotto, Sara and Carbone, Carmine and Piro, Geny and Milella, Michele and Tortora, Giampaolo and Bria, Emilio
Clinical lung cancer, ISSN 1525-7304, 02/2021
Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer
by Leighl, Natasha B and Karaseva, Nina and Nakagawa, Kazuhiko and Cho, Byoung-Chul and Gray, Jhanelle E and Hovey, Tina and Walding, Andrew and Rydén, Anna and Novello, Silvia
European journal of cancer (1990), ISSN 0959-8049, 01/2020, Volume 125, pp. 49 - 57
Non-small-cell lung cancer | Osimertinib | Patient-reported outcomes | EORTC QLQ-LC13 | EORTC QLQ-C30 | Life Sciences & Biomedicine | Oncology | Science & Technology | Antimitotic agents | Care and treatment | Antineoplastic agents | Lung cancer, Non-small cell | Analysis | Patient outcomes | Appetite | Chest | Statistical analysis | Small cell lung carcinoma | Epidermal growth factor receptors | Toxicity | Lung cancer | Cognitive ability | Patients | Cough | Dyspnea | Pain | Deterioration | Respiration | Gefitinib | Significance | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance
by Xie, Zhanhong and Gu, Yingying and Xie, Xiaohong and Lin, Xinqing and Ouyang, Ming and Qin, Yinyin and Zhang, Jiexia and Lizaso, Analyn and Chen, Shuyin and Zhou, Chengzhi
Clinical lung cancer, ISSN 1525-7304, 06/2020
Case report | EGFR-TKI | NSCLC | Osimertinib resistance | Double driver
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
by Oxnard, G.R and Yang, J.C.-H and Yu, H and Kim, S.-W and Saka, H and Horn, L and Goto, K and Ohe, Y and Mann, H and Thress, K.S and Frigault, M.M and Vishwanathan, K and Ghiorghiu, D and Ramalingam, S.S and Ahn, M.-J
Annals of oncology, ISSN 0923-7534, 04/2020, Volume 31, Issue 4, pp. 507 - 516
EGFR mutation | non-small cell lung cancer | phase I | osimertinib | combination | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text AURA3 trial: does Tagrisso (osimertinib) have the potential to become the new standard of care for second-line treatment of patients with
by Papadimitrakopoulou, Vassiliki A
Lung cancer management, ISSN 1758-1966, 12/2016, Volume 5, Issue 4, pp. 159 - 162
NSCLC | osimertinib | T790M
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report
by Yang, James Chih-Hsin and Shepherd, Frances A and Kim, Dong-Wan and Lee, Gyeong-Won and Lee, Jong Seok and Chang, Gee-Chen and Lee, Sung Sook and Wei, Yu-Feng and Lee, Yun Gyoo and Laus, Gianluca and Collins, Barbara and Pisetzky, Francesca and Horn, Leora
Journal of thoracic oncology, ISSN 1556-0864, 05/2019, Volume 14, Issue 5, pp. 933 - 939
Osimertinib | Non–small cell lung cancer | Durvalumab | Combination | EGFR | Respiratory System | Oncology | Life Sciences & Biomedicine | Science & Technology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib
by Gu, Jiajia and Qian, Luxi and Zhang, Guojing and Mahajan, Nupam P and Owonikoko, Taofeek K and Ramalingam, Suresh S and Sun, Shi-Yong
Lung cancer (Amsterdam, Netherlands), ISSN 0169-5002, 12/2020, Volume 150, pp. 26 - 35
Osimertinib | Acquired resistance | ACK1 | Lung cancer | EGFR | Apoptosis | Tyrosine | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Response to Osimertinib in a NSCLC Patient Harboring EGFR V843I Germ-Line Mutation
by Song, Huihui and Chen, Yang and Yan, Zhengqing and Sun, Guangyuan and Shi, Zhaoquan
Lung cancer (Amsterdam, Netherlands), ISSN 0169-5002, 12/2020, Volume 150, pp. 247 - 248
Germ-line mutation | NSCLC | Tyrosine kinase inhibitor | EGFR V843I | osimertinib | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.